Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Operating Income: 2016-2025

Historic Operating Income for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$27.4 million.

  • UroGen Pharma's Operating Income fell 56.09% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.4 million, marking a year-over-year decrease of 59.32%. This contributed to the annual value of -$96.8 million for FY2024, which is 47.68% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Operating Income is -$27.4 million, which was up 33.93% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Operating Income ranged from a high of -$13.5 million in Q3 2023 and a low of -$41.4 million during Q2 2025.
  • Over the past 3 years, UroGen Pharma's median Operating Income value was -$25.7 million (recorded in 2024), while the average stood at -$24.4 million.
  • As far as peak fluctuations go, UroGen Pharma's Operating Income surged by 40.81% in 2021, and later tumbled by 89.32% in 2024.
  • Quarterly analysis of 5 years shows UroGen Pharma's Operating Income stood at -$19.9 million in 2021, then declined by 1.84% to -$20.3 million in 2022, then rose by 27.97% to -$14.6 million in 2023, then slumped by 89.32% to -$27.7 million in 2024, then crashed by 56.09% to -$27.4 million in 2025.
  • Its Operating Income was -$27.4 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$36.9 million in Q1 2025.